Top

Published in:

01-07-2009

The thrombocytopenia of WAS: a familial form of ITP?

Author: Ted S. Strom

Published in: Immunologic Research | Issue 1-3/2009

Abstract

In the first report of the concurrent immunodeficiency, thrombocytopenia, and eczema that we now call the Wiskott-Aldrich Syndrome (WAS), Alfred Wiskott asked whether it could be a familial form of Werlhof’s disease (now called ITP). This review summarizes what is known about platelet production, consumption, and function in clinical and murine WAS. Both platelet production and consumption are affected by WASP deficiency. Likely molecular mechanisms have been identified for the former process, but remain problematic for the latter. Recent data in a murine model suggest that WASP deficiency could increase both the incidence of antiplatelet antibodies and susceptibility to their enhancement of platelet consumption. Wiskott's original speculation about the relationship between WAS and ITP may need to be reconsidered.

Wiskott A. Familiarer, angeborener morbus werlhofii. Monatsschrift fur kinderheilkunde. 1936;68:212–6.

Aldrich R, et al. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics. 1954;13:133–9.PubMed

Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott–Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104:4010–9.PubMedCrossRef

Takenawa T, Suetsugu S. The WASP-WAVE protein network: connecting the membrane to the cytoskeleton. Nat Rev Mol Cell Biol. 2007;8:37–48.PubMedCrossRef

Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott–Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity. 1998;9:81–91.PubMedCrossRef

Zhang J, Shehabeldin A, da Cruz LA, et al. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott–Aldrich syndrome protein-deficient lymphocytes. J Exp Med. 1999;190:1329–42.PubMedCrossRef

Klein C, Nguyen D, Liu CH, et al. Gene therapy for Wiskott Aldrich Syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood. 2003;101:2159–66.PubMedCrossRef

Strom TS, Turner SJ, Andreansky S, et al. Defects in T-cell-mediated immunity to influenza virus in murine Wiskott–Aldrich Syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. Blood. 2003;102:3108–16.PubMedCrossRef

Dupre L, Marangoni F, Scaramuzza S, et al. Efficacy of gene therapy for Wiskott–Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation. Hum Gene Ther. 2006;17:303–13.PubMedCrossRef

10.

Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38:1–10.PubMed

11.

George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–40.PubMed

12.

Pearson HA, Shulman NR, Oski FA, Eitzman DV. Platelet survival in Wiskott–Aldrich syndrome. J Pediatr. 1966;68:754–60.PubMedCrossRef

13.

Grottum KA, Hovig T, Holmsen H, Abrahamsen AF, Jeremic M, Seip M. Wiskott–Aldrich syndrome: qualitative platelet defects and short platelet survival. Br J Haematol. 1969;17:373–88.PubMedCrossRef

14.

Baldini MG. Nature of the platelet defect in the Wiskott–Aldrich syndrome. Ann N Y Acad Sci. 1972;201:437–44.PubMedCrossRef

15.

Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ. The Wiskott–Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood. 1980;55:243–52.PubMed

16.

Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;66:1105–9.PubMed

17.

Prislovsky A, Marathe B, Hosni A, et al. Rapid platelet turnover in WASP(−) mice correlates with increased ex vivo phagocytosis of opsonized WASP(−) platelets. Exp Hematol. 2008;36(907):e901–15.

18.

Mullen C, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott–Aldrich syndrome: long-term followup of 52 cases. Blood. 1993;82:2961–6.PubMed

19.

Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol. 1995;23:996–1001.PubMed

20.

Kuwana M, Okazaki Y, Satoh T, Asahi A, Kajihara M, Ikeda Y. Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med. 2005;118:1026–33.PubMedCrossRef

21.

Salvagno GL, Montagnana M, Degan M, et al. Evaluation of platelet turnover by flow cytometry. Platelets. 2006;17:170–7.PubMedCrossRef

22.

Robinson M, MacHin S, Mackie I, Harrison P. In vivo biotinylation studies: specificity of labelling of reticulated platelets by thiazole orange and mepacrine. Br J Haematol. 2000;108:859–64.PubMedCrossRef

23.

Semple JW, Siminovitch KA, Mody M, et al. Flow cytometric analysis of platelets from children with the Wiskott–Aldrich syndrome reveals defects in platelet development, activation and structure. Br J Haematol. 1997;97:747–54.PubMedCrossRef

24.

Matzdorff A, Kemkes-Matthes B, Pralle H. Microparticles and reticulated platelets in Wiskott–Aldrich syndrome patients. Br J Haematol. 2000;109:673.PubMedCrossRef

25.

Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott–Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995;9:414–7.PubMedCrossRef

26.

Vermi W, Blanzuoli L, Kraus MD, et al. The spleen in the Wiskott–Aldrich syndrome: histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the disease. Am J Surg Pathol. 1999;23:182–91.PubMedCrossRef

27.

Snover DC, Frizzera G, Spector BD, Perry GSIII, Kersey JH. Wiskott–Aldrich syndrome: histopathologic findings in the lymph nodes and spleens of 15 patients. Hum Pathol. 1981;12:821–31.PubMedCrossRef

28.

Kajiwara M, Nonoyama S, Eguchi M, et al. WASP is involved in proliferation and differentiation of human haemopoietic progenitors in vitro. Br J Haematol. 1999;107:254–62.PubMedCrossRef

29.

Sabri S, Foudi A, Boukour S, et al. Deficiency in the Wiskott–Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood. 2006;108:134–40.PubMedCrossRef

30.

Andreansky S, Liu CH, Turner SJ, et al. WASP-mice exhibit defective immune responses to Influenza A Virus, Streptococcus pneumoniae, and Mycobacterium bovis BCG. Exp Hematol. 2005;33:443–51.PubMedCrossRef

31.

Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007;317:1767–70.PubMedCrossRef

32.

Haddad E, Cramer E, Riviere C, et al. The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation. Blood. 1999;94:509–18.PubMed

33.

Luthi JN, Gandhi MJ, Drachman JG. X-linked thrombocytopenia caused by a mutation in the Wiskott–Aldrich syndrome (WAS) gene that disrupts interaction with the WAS protein (WASP)-interacting protein (WIP). Exp Hematol. 2003;31:150–8.PubMedCrossRef

34.

Schulze H, Korpal M, Hurov J, et al. Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. Blood. 2006;107:3868–75.PubMedCrossRef

35.

Marone G, Albini F, di Martino L, Quattrin S, Poto S, Condorelli M. The Wiskott–Aldrich syndrome: studies of platelets, basophils and polymorphonuclear leucocytes. Br J Haematol. 1986;62:737–45.PubMedCrossRef

36.

Stormorken H, Hellum B, Egeland T, Abrahamsen TG, Hovig T. X-linked thrombocytopenia and thrombocytopathia: attenuated Wiskott–Aldrich syndrome. Functional and morphological studies of platelets and lymphocytes. Thromb Haemost. 1991;65:300–5.PubMed

37.

Gross BS, Wilde JI, Quek L, Chapel H, Nelson DL, Watson SP. Regulation and function of WASp in platelets by the collagen receptor, glycoprotein VI. Blood. 1999;94:4166–76.PubMed

38.

Shcherbina A, Rosen FS, Remold-O’Donnell E. Pathological events in platelets of Wiskott–Aldrich syndrome patients. Br J Haematol. 1999;106:875–83.PubMedCrossRef

39.

Yoo Y, Wu X, Guan JL. A novel role of the actin-nucleating Arp2/3 complex in the regulation of RNA polymerase II-dependent transcription. J Biol Chem. 2007;282:7616–23.PubMedCrossRef

40.

Wu X, Yoo Y, Okuhama NN, Tucker PW, Liu G, Guan JL. Regulation of RNA-polymerase-II-dependent transcription by N-WASP and its nuclear-binding partners. Nat Cell Biol. 2006;8:756–63.PubMedCrossRef

41.

Rengan R, Ochs HD, Sweet LI, et al. Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells. Blood. 2000;95:1283–92.PubMed

42.

Falet H, Hoffmeister KM, Neujahr R, Hartwig JH. Normal Arp2/3 complex activation in platelets lacking WASp. Blood. 2002;100:2113–22.PubMed

43.

Oda A, Ochs HD, Druker BJ, et al. Collagen induces tyrosine phosphorylation of Wiskott–Aldrich syndrome protein in human platelets. Blood. 1998;92:1852–8.PubMed

44.

Oda A, Ochs HD, Lasky LA, et al. CrkL is an adapter for Wiskott–Aldrich syndrome protein and Syk. Blood. 2001;97:2633–9.PubMedCrossRef

45.

Soriani A, Moran B, de Virgilio M, et al. A role for PKCtheta in outside-in alpha(IIb)beta3 signaling. J Thromb Haemost. 2006;4:648–55.PubMedCrossRef

46.

Tsuboi S, Nonoyama S, Ochs HD. Wiskott–Aldrich syndrome protein is involved in alphaIIb beta3-mediated cell adhesion. EMBO Rep. 2006;7:506–11.PubMed

47.

Stoll D, Cines DB, Aster RH, Murphy S. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood. 1985;65:584–8.PubMed

48.

Tomer A, Hanson SR, Harker LA. Autologous platelet kinetics in patients with severe thrombocytopenia: discrimination between disorders of production and destruction. J Lab Clin Med. 1991;118:546–54.PubMed

49.

Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80:33–40.PubMedCrossRef

50.

Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol. 2008;Suppl:3–8.

51.

George JN. Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins. Blood. 1990;76:859–70.PubMed

52.

Santoso S, Kiefel V, Mueller-Eckhardt C. Redistribution of platelet glycoproteins induced by allo- and autoantibodies. Thromb Haemost. 1987;58:866–71.PubMed

53.

White JG, Escolar G. Induction of receptor clustering, patching, and capping on surface-activated platelets. Lab Invest. 1990;63:332–40.PubMed

54.

McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol. 2003;25(Suppl 1):S57–61.PubMedCrossRef

55.

Metcalfe P. Platelet antigens and antibody detection. Vox Sang. 2004;87(Suppl 1):82–6.PubMedCrossRef

56.

Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887–95.PubMedCrossRef

57.

McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9.PubMedCrossRef

58.

Kurata Y, Hayashi S, Kiyoi T, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol. 2001;115:656–64.PubMedCrossRef

59.

Sakakura M, Wada H, Abe Y, et al. Usefulness of measurement of reticulated platelets for diagnosis of idiopathic thrombocytopenic purpura. Clin Appl Thromb Hemost. 2005;11:253–61.PubMedCrossRef

60.

Parker RI, Siegel RS, Ratajczak MZ, Gewirtz AM. Deficient in vitro megakaryocytopoiesis and decreased in vivo platelet turnover in children and young adults with chronic thrombocytopenia. J Pediatr Hematol Oncol. 1998;20:196–201.PubMedCrossRef

61.

Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2002;43:2083–92.PubMedCrossRef

62.

Notarangelo LD, Mazza C, Giliani S, et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood. 2002;99:2268–9.PubMedCrossRef

63.

Chang CS, Li CY, Cha SS. Chronic idiopathic thrombocytopenic purpura. Splenic pathologic features and their clinical correlation. Arch Pathol Lab Med. 1993;117:981–5.PubMed

64.

Humblet-Baron S, Sather B, Anover S, et al. Wiskott–Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest. 2007;117(2):407–18.PubMedCrossRef

65.

Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott–Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111:e622–7.PubMedCrossRef

66.

Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med. 2001;193:855–62.PubMedCrossRef

67.

Olsson M, Bruhns P, Frazier WA, Ravetch JV, Oldenborg PA. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005;105:3577–82.PubMedCrossRef

68.

Oldenborg PA, Gresham HD, Chen Y, Izui S, Lindberg FP. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood. 2002;99:3500–4.PubMedCrossRef

69.

Leverrier Y, Lorenzi R, Blundell MP, et al. Cutting edge: the Wiskott–Aldrich syndrome protein is required for efficient phagocytosis of apoptotic cells. J Immunol. 2001;166:4831–4.PubMed

70.

Lorenzi R, Brickell PM, Katz DR, Kinnon C, Thrasher AJ. Wiskott–Aldrich syndrome protein is necessary for efficient IgG-mediated phagocytosis. Blood. 2000;95:2943–6.PubMed

71.

Tsuboi S, Meerloo J. Wiskott–Aldrich syndrome protein is a key regulator of the phagocytic cup formation in macrophages. J Biol Chem. 2007;282:34194–203.PubMedCrossRef

72.

Corash L, Shafer B, Blaese RM. Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott–Aldrich syndrome. Blood. 1985;65:1439–43.PubMed

73.

Kanegane H, Nomura K, Miyawaki T, et al. X-linked thrombocytopenia identified by flow cytometric demonstration of defective Wiskott–Aldrich syndrome protein in lymphocytes. Blood. 2000;95:1110–1.PubMed

74.

Litzman J, Jones A, Hann I, Chapel H, Strobel S, Morgan G. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott–Aldrich syndrome. Arch Dis Child. 1996;75:436–9.PubMedCrossRef

75.

Kelton JG, Powers PJ, Carter CJ. A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. Blood. 1982;60:1050–3.PubMed

76.

Mathew P, Conley ME. Effect of intravenous gammaglobulin (IVIG) on the platelet count in patients with Wiskott–Aldrich syndrome. Pediatr Allergy Immunol. 1995;6:91–4.PubMedCrossRef

77.

Zhang H, Schaff UY, Green CE, et al. Impaired integrin-dependent function in Wiskott–Aldrich syndrome protein-deficient murine and human neutrophils. Immunity. 2006;25:285–95.PubMedCrossRef

Title: The thrombocytopenia of WAS: a familial form of ITP?
Author: Ted S. Strom
Publication date: 01-07-2009
Publisher: Humana Press Inc
Published in: Immunologic Research / Issue 1-3/2009
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-008-8069-2

At a glance: The STEP trials

Springer Medicine

The thrombocytopenia of WAS: a familial form of ITP?

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-3/2009

Mutations of the Wiskott–Aldrich Syndrome Protein affect protein expression and dictate the clinical phenotypes

Characterization of cultured thymus tissue used for transplantation with emphasis on promiscuous expression of thyroid tissue-specific genes

Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID

Results and long-term outcome in 39 patients with Wiskott–Aldrich syndrome transplanted from HLA-matched and -mismatched donors

FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning

Single-center analysis of long-term outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency